The Danish PNS program

Including NIPT - but not yet PE

Olav Bjørn Petersen
Ass. professor, consultant, Ph.D.
Center for Fetal Diagnostics www.cffd.dk
Aarhus University Hospital Skejby
obp@clin.au.dk





Danish prenatal healthcare







National guideline 2004 Updated 2017

RETNINGSLINJER FOR FOSTERDIAGNOSTIK

- prænatal information, risikovurdering, rådgivning og diagnostik

2004



SUNDHEDSSTYRELSEN







Danish PNS 2018 - purpose

- A better start for the child with special needs:
 - The professionals can be prepared "born at the right place, with the right people available at - and after delivery"
 - The parents can be prepared for a child with special needs
- NOT specific Down Syndrome screening





Danish PNS 2018 - Context

- Support reproductive autonomy:
 - Support couples decisions in agreement with their belief, culture and ethics
 - Continuing pregnancy or TOP are equal alternatives in case of severe disease





Danish PNS 2018 - Context

- Free of charge offer to all women of:
 - 1st Trimester scan
 - Risk assessment for chromosomal anomalies
 - 2nd Trimester scan





The NIPT wave?



Retningslinjer for fosterdiagnostik

PRÆNATAL INFORMATION, RISIKOVURDERING, RÅDGIVNING OG DIAGNOSTIK











Atypical abnormal chromosomal anomalies – important?







Does atypicals matters?

Original Research

Chromosome Abnormalities Detected by **Current Prenatal Screening and Noninvasive Prenatal Testing** (Obstet Gynecol 2014;124:979-86)

DOI: 10.1097/AOG.00000000000000452

Mary E. Norton, MD, Laura L. Jelliffe-Pawlowski, PhD, and Robert J. Currier, PhD

17% atypical likely missed by NIPT

Ultrasound Obstet Gynecol 2014; 43: 265-271 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.13270

Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening

O. B. PETERSEN*#, I. VOGEL†#, C. EKELUND‡, J. HYETT§, A. TABOR ‡, the Danish Fetal Medicine Study Group and the Danish Clinical Genetics Study Group

- •23% atypical likely missed by NIPT
- Prevalence atypical:
 - Total population: 0.14%
 - •PAPP-A<0,2 MoM= 4.2%
 - •Free ß-hCG<0,2 MoM=7.1%
 - •Free ß-hCG >5 MoM=0.5%





Does atypicals matters?

Ultrasound Obstet Gynecol 2018; 51: 487–492 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.18979



Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing

A. LINDQUIST^{1,2,3}, A. POULTON¹, J. HALLIDAY^{1,4} and L. HUI^{1,2,3}

Prevalence atypical:

- •PAPP-A<0.2 MoM= 6.9%
- •Free ß-hCG <0.2 MoM=5.2%





Does atypicals matters?

Ultrasound Obstet Gynecol 2018; 51: 445–452 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.17533



Frequency of submicroscopic chromosomal aberrations in pregnancies without increased risk for structural chromosomal aberrations: systematic review and meta-analysis

M. I. SREBNIAK¹, M. JOOSTEN¹, M. F. C. M. KNAPEN^{2,3}, L. R. ARENDS^{4,5}, M. POLAK⁴, S. VAN VEEN¹, A. T. J. I. GO² and D. VAN OPSTAL¹

MA (years)	Risk for Down syndrome (Hook et al. ⁵ , minimal prevalence)	Risk for clinically relevant microscopic chromosomal aberrations (Hook et al. ⁵)	Risk for patho submicroscopic ab associated with syndron disorders (this r	errations nic early-onset	Risk for all chromosomal aberrations (both microscopic and submicroscopic)
20	1:2000	1:555	1:270		1:179
30	1:1111	1:384	1:270		1:159
35	1:400	1:178	1:270		1:108
40	1:117	1:63	1:270		1:51
45	1:35	1:19	1:270	J	1:17





Does testtype matters?

Original Research

ajog.org

OBSTETRICS

Chromosomal abnormalities not currently detected by cell-free fetal DNA: a retrospective analysis at a single center

JUNE 2016 American Journal of the content of the currently detected by cell-free fetal DNA: a retrospective analysis at a single center

JUNE 2016 American Journal of Obstetrics & Gynecology 729.61

Hagit Shani, MD; Tamar Goldwaser, MD; Jennifer Keating, MS; Susan Klugman, MD

•45% atypical likely missed by NIPT





Danish PNS 2018

GP informs about the prenatal program

- + Double test (w 9-10)
- + Referral for 1st Trim ULS
 - CRL/EDD + gross anomalies
 - +/- cFTS risk assessment

• + 2nd trim ULS





@ cFTS high risk

- T21 risk >1:300
- T18/13 risk >1:150
- Offered
 - Invasive test (CVS), or
 - NIPT (as non-equal screening test)





@ cFTS high risk (new)

- Single factors:
 - $-NT \ge 3.5$ mm, or
 - Free β-hCG ≥ 5 MoM, or
 - Free β -hCG or PAPP-A < 0.2 MoM, or
 - Maternal age ≥ 45 year
- Offered invasive test (CVS) with CMA
 - Or NIPT as a non-equal option





National guideline on CMA



CMA recommended as the first line prenatal invasive genetic analysis

- Unless..
- PCR?

FØTO-Sandbjerg guideline 2018

Tite

Prænatal kromosom mikroarray analyse (CMA)

Forfatter

Ida Vogel, overlæge, Klinisk Genetisk afdeling, Aarhus Universitetshospital
Christina Fagerberg, overlæge, Klinisk Genetisk afdeling, Odense Universitetshospital
Iben Bache, afdelingslæge, Klinisk Genetisk klinik, Rigshospitalet
Charlotte Ekelund, overlæge, Center for Føtalmedicin og graviditet, Obstetrisk klinik, Rigshospitalet
Eva Hoseth, overlæge, Gynækologisk-obstetrisk afdeling, Aalborg Universitetshospital
Lone Nørgaard, overlæge, Center for Føtalmedicin og graviditet, Obstetrisk klinik, Rigshospitalet
Lene Sperling, overlæge, Føtalmedicinsk klinik, Odense Universitetshospital
Lillian Skibsted, overlæge, Sjællands Universitetshospital, Roskilde
Ann Tabor, professor, Center for Føtalmedicin og graviditet, Obstetrisk klinik, Rigshospitalet
Olav Bjørn Petersen, overlæge, Afd. for Kvindesvgdomme og Fødsler, Aarhus Universitetshospital







Results, 1 year experience

"Isolated" T21 Risk > 1:300, n=575

Ultrasound Obstet Gynecol 2018
Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.17548

Chromosomal microarray as primary diagnostic genomic tool for pregnancies at increased risk within a population-based combined first-trimester screening program


I. VOGEL^{1,2,3}, O. B. PETERSEN^{2,4}, R. CHRISTENSEN^{1,3}, J. HYETT⁵, S. LOU^{2,6} and E. M. VESTERGAARD^{1,2,3}







51 Abnormal using CMA



13%

T21 Risk > 1:300, n=575 180k array-CGH

Detectable also by

- NIPT
- Cytogenetic karyotype
- •CMA








Distribution of abnormal CMA's

T21 Risk > 1:300, n=575








INIPT could detect 87%





INIPT could detect 28%





Contingency: CVS only >1:50 +NIPT 1:50 to 1:300??

Would have missed 93% of the pathogenic, susceptibility and likely pathogenic CNVs





1st trimester screening for PE in DK?







Screening for pre-eclampsia in the first trimester A Danish Multicenter Study

Purpose:

- To examine the performance of screening for preeclampsia in the first trimester of pregnancy in an unselected Danish population
- To evaluate the attitude among pregnant women towards this screening





Screening for pre-eclampsia in the first trimester A Danish Multicenter Study

Method:

- We plan to include 8300 pregnant women in five University Hospitals
- 300 women will be invited to participate in a questionnaire study





Screening for pre-eclampsia in the first trimester A Danish Multicenter Study

Current cFTS





•week 9

•week 12



•week 40

Risk assessment calculation

•+/- PF

•+ PE screening











- •9 month inclusion period
- •Results in 2020





Conclusion

cFTS identifies (a proportion of) women @ risk of atypical chromosomal anomalies

Increased diagnostic yield by CVS+CMA

1st Trim screening for PE: Awaiting DK validation study









Aarhus University Hospital/
Center for Fetal Diagnostics:
Ida Vogel
Stina Lou
Puk Sandager
Else Marie Vestergaard
Helle Hørby

National Hospital/Rigshospitalet, Copenhagen:
Ann Tabor

Charlotte Ekelund Karin Sundberg







And many more!!









